Induced pluripotent stem cells gain momentum as new methods and clinical successes drive drug development

Induced pluripotent stem cells (iPSCs) are moving from a research curiosity to a practical tool in drug development. After years of steady progress, recent advances are bringing iPSCs into the spotlight for both laboratory and clinical work.

Two key trends are accelerating this shift. First, the rapid adoption of new approach methodologies (NAMs) is providing more reliable and scalable ways to generate and test iPSC-derived cells. These methods reduce reliance on animal models and improve the relevance of pre‑clinical data.

Second, an expanding body of clinical evidence, especially in cell replacement therapies, is demonstrating that iPSC‑derived products can be safe and effective in patients. The author, who works on iPSC manufacturing at FUJIFILM Cellular Dynamics, notes that these developments are helping turn iPSCs into a viable platform for therapeutic development.